Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Plain-language summary

This phase 2 randomized controlled trial published in the New England Journal of Medicine evaluated tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis over 52 weeks. Researchers found that tirzepatide was significantly more effective than placebo at resolving MASH without worsening fibrosis. The findings suggest that tirzepatide's dual GIP/GLP-1 receptor agonism may offer a meaningful therapeutic approach for liver disease beyond its established metabolic effects.